Jump to content

Dornase alfa

From Wikipedia, the free encyclopedia
(Redirected from Dilor-400)
Dornase alfa
Clinical data
Trade namesPulmozyme
AHFS/Drugs.comMonograph
MedlinePlusa694002
License data
Pregnancy
category
Routes of
administration
Inhalation
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.029.685 Edit this at Wikidata
Chemical and physical data
FormulaC1321H1999N339O396S9
Molar mass29254.04 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis.[3] It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.[3] Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions.[3] It is produced in Chinese hamster ovary cells.[3]

Medical uses

[edit]

Dornase alfa is indicated for the management of people with cystic fibrosis to improve pulmonary function.[3]

Society and culture

[edit]
[edit]

Dornase alfa is an orphan drug.[4]

Research

[edit]

Dornase alfa has been shown to improve lung function in non-cystic fibrosis pre-term infants atelectasis.[5][6]

References

[edit]
  1. ^ a b Product guildlink.com.au
  2. ^ "Pulmozyme Product information". Health Canada. 25 April 2012. Retrieved 9 January 2023.
  3. ^ a b c d e f "Pulmozyme- dornase alfa solution". DailyMed. 21 October 2020. Retrieved 9 January 2023.
  4. ^ Collier, Joe (1 September 1995). "Dornase-alfa and orphan drugs". The Lancet. 346 (8975): 633. doi:10.1016/S0140-6736(95)91460-9. PMID 7651014. S2CID 5456247.
  5. ^ Erdeve O, Uras N, Atasay B, Arsan S (2007). "Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series". Croat Med J. 48 (2): 234–9. PMC 2080511. PMID 17436388.
  6. ^ Hendriks T, de Hoog M, Lequin MH, Devos AS, Merkus PJ (2005). "DNase and atelectasis in non-cystic fibrosis pediatric patients". Crit Care. 9 (4): R351-6. doi:10.1186/cc3544. PMC 1269442. PMID 16137347.